Lookback study for transfusion- related HBV infection in Japan Tokyo Metropolitan Red Cross Blood Center Masahiro Satake.

Slides:



Advertisements
Similar presentations
A PROSPECTIVE STUDY OF POLYMERASE CHAIN REACTION TESTING ON POOLED PLASMA VS. INDIVIDUAL DONATION HIV P24 TESTING.
Advertisements

Managing patients with chronic viral hepatitis who need renal replacement therapy. Thursday 5 th February Dr Allister Grant Leicester Liver Unit.
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013.
Nucleic Acid Testing vs Infectivity Michael P. Busch, M.D., Ph.D. Blood Centers of the Pacific Blood Systems, Inc. EPFA, Lisbon Portugal May, 2001.
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
The Safety of the Blood Supply
Acute Viral Hepatitis. Viral Hepatitis Infectious: Hepatitis A Infectious: Hepatitis A Serum : Hepatitis B, D Serum : Hepatitis B, D NANB : Hepatitis.
Transfusion Transmission of HIV 1. Past & Current Risk Estimates of Transfusion-Transmitted HIV Infection 2. Layers of Safety in Protection of the Blood.
F. Kourgia, M. Vini, E. Zervou
Epidemiology and Prevention of Viral Hepatitis A to E: Hepatitis Branch Centers for Disease Control and Prevention An Overview.
Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.
Deferral of MSM: Policy Analysis by Andrew I. Dayton.
Role of Clinicians in Promoting Voluntary Blood Donation Dr. Anju Verma.
Management of Risk and Blood Availability in Donor Populations with High Prevalence of Blood Borne Pathogens Ravi Reddy IBSF Meeting 20 March 2015.
Testing Source Plasma for Hepatitis B Virus by Nucleic Acid Testing Blood Products Advisory Committee Meeting Blood Products Advisory Committee Meeting.
By: Students of Class 9th
Prevalence and risk relationships of tattoo, acupuncture and skin/body piercing histories among American Red Cross blood donors Sharyn Orton, MSPH, PhD.
Terry Kotrla, MS, MT(ASCP)BB MLAB 2431 Immunohematology Unit 1 Part 2 Blood Collection.
Immunohematology (Blood Bank) CLS 245. What is Immunohematology? It is the study of Antigen-Antibody reaction as they relate to blood disorder.
The Journey of Blood. Blood - the life source Slide 1: Blood is a scarce and vital resource which saves lives and improves the health of millions. Its.
21 August 2015 Samreen Ijaz Virus Reference Department Health Protection Agency Indigenous HEV infection in the UK: a hazard for blood donation?
Pooled Source Plasma NAT for HIV-1 An Update from the Bayer HIV-1 IND Study Barbara Masecar Bayer Corporation Raleigh, NC Blood Products Advisory Committee.
BioLife Plasma Services Experience with HBV NAT Testing
And the order changeth …. Evolving protocols for TTI testing
Adult Viral Hepatitis Update Roxanne Ereth, MPH, BS Hepatitis C Program Manager Adult Viral Hepatitis Prevention Coordinator.
PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
Viral Hepatitis Australian Family Physician Vol. 30 No.5, May 2001 Presented by 郭詠怡 Date presented:25/8/2003.
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
Hepatitis B Virus Dr R V S N Sarma., M.D., [SLIDE 1] Title Slide
21th VHPB meeting on “Prevention of viral hepatitis in Italy: lessons learnt and the way forward” Catania, 7-8 november 2002 RESIDUAL RISK OF TRANSFUSION-
MEDICAL TESTING Doctor requires information Patient sample collection
Maria Rios, Ph.D. CBER/FDA Blood Products Advisory Committee May 1st, WNV Epidemiology & FDA’s Recommendations on the Use of NAT to Reduce the.
Jade Rotondo March 20, 2012 Grade 7 B168.  This project is going to be about our blood that functions and transfers important things in our body. Jade.
The Journey of Blood. Blood- the life source Slide 1: Blood is a scarce and vital national resource which cannot be synthesized. About 80 million unit.
Occult hepatitis B virus (HBV) and hepatitis C virus (HCV) viremia in women with and at-risk for HIV/AIDS Taylor L, Gholam P, Delong A, Rompalo A, Klein.
Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
TRANSPORT IN PLANTS AND ANIMALS BLOOD GROUPS AND BLOOD TRANSFUSION Lesson objectives; By the end of the lesson the learner should be able to explain the.
Module 1: The Journey of Blood: Donation to Distribution Transfusion Training Workshop KKM 2012.
HBV screening Further improvement of blood safety based on the knowledge deduced from the results on analysis of the donor’s sera positive for HBV DNA.
Our tryst with Nucleic Acid Testing Dolly Daniel, Dept of Transfusion Medicine, CMC, Vellore.
BLOOD TRANSFUSION SAFETY: PROGRESS REPORT 142 nd Session of the Executive Committee June 2008, Washington DC Pan American Health Organization 142.
Serology - anti-HCV. anti-HIV, HBsAg NAT - HCV RNA - since 2000
Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVII, Paris, Paris 2004 B19 Overview of Testing for Blood Banks W. Kurt Roth Red Cross Blood Transfusion.
Blood Groups and Transfusions. Blood Loss Body is only able to compensate for minor losses – 15-30% cause weakness – >30% body goes into shock Can be.
What is Hepatitis? General: inflammation of liver parenchyma cells
Epidemiology of Transfusion Transmitted Disease Sharyn Orton, MT(ASCP)SBB, M.S.P.H, Ph.D. candidate Project Leader, Transmissible Diseases Department American.
Slide 1 "CJD Lookback Study" (Research Study to Assess the Risk of Blood Borne Transmission of CJD) American Red Cross Blood Services TSEAC October 14,
Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVI, Langen 3 rd July 2003 Immediate Parvo B19 NAT testing of pooled donor samples: logistics and.
Holland Laboratory David A. Leiby, PhD Transmissible Diseases Department American Red Cross Holland Laboratory and Department of Microbiology and Tropical.
1 Update on Study to Further Define the Incidence of T. cruzi Infection in the US Blood Donor Population Susan L. Stramer, PhD American Red Cross BPAC.
Prevention of Viral Hepatitis B in Republic of Korea Ok Park, M.D., Ph.D., MPH Vaccine-Preventable Disease Control & National Immunization Program Korea.
TOPIC: Immunity AIM: What are some disorders of the immune system?
PI project: Hepatitis B prophylaxis in patients with malignancies
Hepatitis C: Overview and Epidemiology
Blood transfusion complications Infectious & non infectious
In The Name of God.
K A U H Blood bank Wesaam Al-Sheyyab.
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
2015 Haemovigilance Report Tables and Figures
Dr Iyat Abdul Sattar A study on the clinical & serolological markers of HBV among patients with chronic HBV infection in Babylon Dr Monem Makki Alshok.
Implementing NAT& Universal Parasitic Screening for Blood Donors
MICROBIOLOGY PRACTICAL
R. Cavallo  Clinical Microbiology and Infection 
Evaluation of the Patient With HCV Infection
HBV/G Infection of an Apheresis Donor
به نام خداوند بخشنده مهربان
Intraoperative Cell Salvage
SoGAT meeting XXI May (2009), Brussels, Belgium
Presentation transcript:

Lookback study for transfusion- related HBV infection in Japan Tokyo Metropolitan Red Cross Blood Center Masahiro Satake

Aliquots from all donations have been stored since When necessary, each aliquot was investigated using individual donation-NAT (ID-NAT). Subjects for the study : converters for HBs-Ag, HBc-Ab, HCV-Ab, HIV-Ab, screening NAT for HBV, HCV or HIV during April 1999 and February 2005 Lookback study in Japan

ID-NAT results in repository tubes from seroconverted or NAT-converted donors No. of ID-NAT performed No. of positive tubes Positivity rate (%) HBV20, HCV4, HIV1, total 26, (‘99 April ~ ’05 February)

No. of HBV ID-NAT positive but pool-NAT negative donors estimated by lookback study Conversion / year ID-NAT positive No. of ID-NAT positive donors HBV-pool NAT %3.0 HB s -Ag % 4.6 HB c -Ab %32.6 total % 40.2 These donations do not directly relate to infectivity.

The infectivity of HBV-ID-NAT positive components No. of ID-NAT positive donation 267 No. of components released 321 transfused ・・・・・・・・・・・ discarded ・・・・・・・・・・・ unknown ・・・・・・・・・・・ Outcome of transfused patients ( 191 reports available ) HBs-Ag conversion HBV-DNA conversion HBs-Ab conversion positive, but no information before transfusion 7 markers not changed dead discharged etc

HBV infected Undetermined No change others Infectious risk when transfused with ID-NAT positive blood 11 / 78 ~ 18 / 78 The infectivity of HBV-ID NAT-positive components 6 ~ 10 HBV infections per year

Infectivity of HBV ID-NAT positive components ComponentInfected No change totalinfectivity Window period (HBcAb -) % (10/31) Chronic carrier (HBcAb +) % (1/40) Infectivity of W.P. component is 13 times as high as that from chronic carrier.

Implicated components component From window period From chronic carrier RBC 5 / 10 (50%) 0 / 19 FFP 3 / 10 (30%) 1 / 18 (6%) Platelet 2 / 4 (50%) 0 / 1

Established cases for HBV infection Disorders of patients hematologic malignancy2 gastric cancer2 dissecting aortic aneurysm 1 shock due to multiple trauma1 rheumatoid arthritis1 unknown4

ID-NAT in repository tubes --- voluntarily reported HBV cases ---

The risk of HBV infection under current screening algorism including 50p-NAT system SourcesHBV-infection Lookback investigation 6 ~ 10 Voluntary report of infection 5 total 1 1 ~1 5 cases / year

Lookback study for HCV and HIV No. of ID-NAT performed No. of positive tubes HCV 4,371 2 (1 donation before NAT implementation) HIV 1,673 1 (Established infected case) Seroconversion possibly due to nonspecific reaction was also subjected to lookback study.

Estimates for the Occurrence of Transfusion- Transmitted Viral Diseases in Japan HBV HBV+ donation detectable only by ID-NAT : 1 / 150, ~ 15 infection cases per year ( 1 infection / 3.6 ~ 5.4 x 10 5 components ) HCV ( difficult to estimate ) HCV+ donation detectable only by ID-NAT : 1 / 24 million ( 1 component / 4 years ) HIV ( difficult to estimate ) HIV+ donation detectable only by ID-NAT : 1 / 12 million ( 1 component / 2 years )